131I-MIBG Therapy in metastatic phaeochromocytoma and paraganglioma

被引：0
|
作者：
Gonca Kara Gedik
Cornelis A. Hoefnagel
Evert Bais
Renato A. Valdés Olmos
机构：
[1] Hacettepe University School of Medicine,Department of Nuclear Medicine, Faculty of Medicine
[2] The Netherlands Cancer Institute,Department of Nuclear Medicine
[3] The Netherlands Cancer Institute,Department of Medical Oncology
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2008年 / 35卷
关键词：
I-MIBG; Phaeochromocytoma; Paraganglioma; Malignant; Radionuclide therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：725 / 733
页数：8
相关论文
共 50 条
  • [21] Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
    Pryma, Daniel A.
    Chin, Bennett B.
    Noto, Richard B.
    Dillon, Joseph S.
    Perkins, Stephanie
    Solnes, Lilja
    Kostakoglu, Lale
    Serafini, Aldo N.
    Pampaloni, Miguel H.
    Jensen, Jessica
    Armor, Thomas
    Lin, Tess
    White, Theresa
    Stambler, Nancy
    Apfel, Stuart
    DiPippo, Vincent A.
    Mahmood, Syed
    Wong, Vivien
    Jimenez, Camilo
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (05) : 623 - 630
  • [22] Successful Treatment of Coexisting Paraganglioma of the Retroperitoneum and Urinary Bladder by Intermediate-Dose 131I-MIBG Therapy
    Cai, Yi
    Li, Han-Zhong
    Zhang, Yu-Shi
    MEDICINE, 2015, 94 (41)
  • [23] Sequelae and survivorship in patients treated with 131I-MIBG therapy
    Sze, W. C. C.
    Grossman, A. B.
    Goddard, I.
    Amendra, D.
    Shieh, S. C. C.
    Plowman, P. N.
    Drake, W. M.
    Akker, S. A.
    Druce, M. R.
    BRITISH JOURNAL OF CANCER, 2013, 109 (03) : 565 - 572
  • [24] 131I-MIBG negative progressive symptomatic metastatic paraganglioma: response and outcome with 177Lu-DOTATATE peptide receptor radionuclide therapy
    Parghane, Rahul V.
    Talole, Sanjay
    Basu, Sandip
    ANNALS OF NUCLEAR MEDICINE, 2021, 35 (01) : 92 - 101
  • [25] External Beam Radiation Therapy With or Without 131I-MIBG Systemic Radiation Therapy in the Therapy Of Patients With Malignant Pheochromocytoma and Paraganglioma
    Cengel, K. A.
    Lauren, F.
    Alonso-Basanta, M.
    Pryma, D.
    Simone, C. B.
    Findlay, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S615 - S616
  • [26] 131I-MIBG negative progressive symptomatic metastatic paraganglioma: response and outcome with 177Lu-DOTATATE peptide receptor radionuclide therapy
    Rahul V. Parghane
    Sanjay Talole
    Sandip Basu
    Annals of Nuclear Medicine, 2021, 35 : 92 - 101
  • [27] 131I-MIBG Therapy in a Metastatic Small Bowel Neuroendocrine Tumor Patient Undergoing Hemodialysis
    Rahimi, Behruz
    Makis, William
    Riauka, Terence A.
    McEwan, Alexander J. B.
    Morrish, Don
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (05) : 350 - 353
  • [28] Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy
    Bomanji, JB
    Wong, W
    Gaze, MN
    Cassoni, A
    Waddington, W
    Solano, J
    Ell, PJ
    CLINICAL ONCOLOGY, 2003, 15 (04) : 193 - 198
  • [29] Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy 123I-MIBG Versus Posttherapy 131I-MIBG Imaging
    Pandit-Taskar, Neeta
    Zanzonico, Pat
    Hilden, Patrick
    Ostrovnaya, Irina
    Carrasquillo, Jorge A.
    Modak, Shakeel
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (10) : 741 - 748
  • [30] Tumour size:: The only predictive factor for 131I MIBG uptake in phaeochromocytoma and paraganglioma
    Nguyen, HH
    Proye, CAG
    Carnaille, B
    Combemale, F
    Pattou, FN
    Huglo, D
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1999, 69 (05): : 350 - 353
12345